Results from a mouse study of nonalcoholic steatohepatitis were promising for Viking Therapeutics' oral therapy VK2809, now also in a Phase 2 trial.
Jose Marques Lopes, PhD
José holds a PhD in neuroscience from the University of Porto, Portugal. After postdocs at Weill Connell Medicine and Western University, where he studied the processes driving hypertension and Alzheimer’s disease, he moved on in 2016 to a career in science writing and communication. José is the author of several peer-reviewed papers and a book chapter and has presented his research in numerous international meetings.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Jose Marques Lopes, PhD
Dysbiosis, an imbalance in the proportion and activity of bacterial groups of the gut microbiota, can actually aid in liver metabolism…
Type 2 diabetes increases the risk of a person getting a severe liver disease, including cancer, regardless of their body…
Focused ultrasound appears to be able to selectively destroy liver tumors, new research from an EU project shows. Preliminary results…